Gene therapy safe, improves vision in X-linked retinitis pigmentosa in phase 1/2 study
Botaretigene sparoparvovec, an investigational gene therapy, was safe and improved vision in subjects with X-linked retinitis pigmentosa with disease-causing variants in the RPGR gene, according to a press release from MeiraGTx.